03-05-2023 : 769 Pharmacists work as Medical Representative, of which 39 work as Senior Medical Representative * 02-06-2020 : 216 non Pharmacists work as Medical Representative, and 54 work as Senior Medical Representative * 05-06-2023 : In Lebanon, 88 generic medicinal products are more expensive than their Originators * 31-12-2019 : A medicinal product refused in Europe is marketed in Lebanon * 05-06-2023 : At least 332 medicinal products are available on the Lebanese market and are not available in the country of origin * 05-06-2023 : The price of the most expensive medicine available in Lebanon is 30434557 LL * 05-06-2023 : At least 1309 medicinal products are more expensive in Lebanon than in the countries of origin * 01-01-2019 : Daktavira, a generic of Daklinza, is registered in Lebanon but has no public price * 31-12-2019 : 352 medicinal products have been declared as non-marketed or withdrawn * 09-11-2021 : 64.72% of lebanese pharmacists are female * 31-12-2019 : 486 medicines were submitted to the Ministry of Health for a marketing authorization, and 514 medicines were registered to date * 15-06-2018 : The Minister of Public Health, has decided to suspend the commercialization of AB Slim (Ab Care Medical Herbs), which contains sibutramine, sildenafil and phenolphthalein * 01-06-2020 : Some Non-Marketed medicines are still imported * 01-06-2020 : Ixempra, a medicinal product withdrawn in Europe is imported to lebanon * 01-06-2020 : A vaccine made in India, removed from WHO list of prequalified vaccines, is submitted for registration in Lebanon * 01-06-2020 : Lebanon has 14 CROs, and is ranked as one of the largest countries in the world in clinical studies. According to the WHO, 817 clinical studies are currently conducted in Lebanon. * 05-01-2021 : * 01-10-2023 : Adakveo is now withdrawn from use in the European Union due to lack of therapeutic efficacy *
Rifadin Capsules 300mg : | |
Type | Medicine Authorised |
Originator | B |
Agent | Mersaco |
Distributor | Mersaco |
Laboratory | Sanofi |
Responsible Party | Sanofi SpA |
Origin | Italy |
Manufacturer | Sanofi SpA |
Origin | Italy |
ATC | J04AB02 |
Rifadin Capsules 300mg :
Rifadin Capsules 300mg :
Rifadin Capsules 300mg :
Rifadin Capsules 300mg :
Rifadin Capsules 300mg :
Hazard Level |
---|
◼ Major |
◼ Moderate |
◼ Minor |
◼ Safe |
Rifadin Capsules 300mg :
Rifadin Capsules 300mg :
Frequency | Percentage |
---|---|
Very Common | ≥ 1/10 |
Common | ≥ 1/100 - < 1/10 |
Uncommon | ≥ 1/1,000 - < 1/100 |
Rare | ≥ 1/10,000 - < 1/1,000 |
Very Rare | < 1/10,000 |
Unknown | Cannot be Estimated |
Effect | Frequency |
---|---|
Abdominal bloating (Meteorism) | Not known |
Abdominal pain | Not known |
Agranulocytosis | Not known |
ALT increased | Common |
Anaphylactic reactions | Not known |
Anaphylactic shock | Not known |
AST increased | Common |
Blood bilirubin increased | Common |
Blood creatinine increased | Not known |
Blood pressure increased | Not known |
Bone pain | Not known |
Chromaturia | Not known |
Color changes of teeth | Not known |
Decreased appetite | Not known |
Dermatitis allergic | Not known |
Diarrhoea (Diarrhea) | Uncommon |
Disseminated intravascular coagulation | Not known |
DRESS (Drug reaction with eosinophilia and systemic symptoms) | Not known |
Dyspnoea (dyspnea) | Not known |
Eosinophilia | Not known |
Erythema multiforme | Not known |
Fetal-maternal hemorrhage | Not known |
Flu Syndrome | Not known |
Haemolytic anemia | Not known |
Hepatic enzyme increased | Not known |
Hepatitis | Not known |
Hyperbilirubinaemia | Not known |
Hypereosinophilia | Not known |
Hypersensitivity reactions | Not known |
Leucopenia (Leukopenia) | Uncommon |
Lyell Syndrome (Toxic epidermal necrolysis) | Not known |
Menstrual disorder | Not known |
Muscle weakness | Not known |
Myopathy | Not known |
Nausea | Common |
Oedema | Not known |
Phlegm discoloured | Not known |
Porphyria | Not known |
Postpartum hemorrhage | Not known |
Pruritus | Not known |
Pseudomembranous colitis | Not known |
Psychiatric disorders | Not known |
Purpura | Not known |
Renal failure acute (Acute renal insufficiency) (Kidney failure acute) (Renal insufficiency acute) | Not known |
Renal tubular necrosis | Not known |
Respiratory disorder | Not known |
Shock | Not known |
Stevens-Johnson syndrome | Not known |
Sweat discolouration | Not known |
Tear discoloration | Not known |
Thrombocytopenia (Thrombopenia) | Common |
Tubulointerstitial nephritis | Not known |
Urticaria | Not known |
Vasculitides | Not known |
Vomiting | Common |
Rifadin Capsules 300mg :
▲ Most Expensive |
▼ Least Expensive |
P.P. = | Public Price |
P/U = | Price Per Unit |
- Products with same active ingredients |
- Products with same strength |
- Products with same route of administration |
Different Units By MoH Code
Rifadin Capsules 300mg MoH 10238 :
Form | Capsule, hard |
Packaging | Blisters |
Package Size | Box of 100 |
Strength | 300mg |
Public Price | 2990933.96 L.L. |
Stratum | B |
NSSF | ✘ |
Quarantine | ✘ |
Reg. Number | 124319/1 |
Submission date | 2019 |
Registration Year | 02/10/2020 |
Price Comparison
● Country: | Lebanon | |
● Form: | Capsule, hard | |
● Package Size: | Box of 100 | |
● Public Price: | 2990933.96 LBP | ( 2,990,933.96 LBP ) |
● Pack size unit used: | 100 | |
● Cost/Unit: | 29909,34 LBP | ( 29,909.00 LBP ) |
● Pricing Date: | 13/06/2024 |
You have to register to view this info
Drop File